Medifast (MED) to Release Earnings on Monday

Key Points

• Medifast is expected to report its Q2 2025 quarterly earnings on Monday, August 4th, with analysts predicting a loss of ($0.22) per share and revenue of $96.10 million.
• The company last reported earnings in April, missing consensus estimates, and had a revenue of $115.73 million for that quarter, while analysts project earnings of $1 per share for the current fiscal year.
• Hedge funds have been active with their positions in Medifast, with institutions owning 95.51% of the stock; Strs Ohio and Amundi have recently increased their stakes.

Medifast (NYSE:MED - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $96.10 million for the quarter.

Medifast (NYSE:MED - Get Free Report) last posted its earnings results on Monday, April 28th. The specialty retailer reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $115.73 million during the quarter, compared to analysts' expectations of $114.85 million. Medifast had a positive return on equity of 6.63% and a negative net margin of 1.29%. On average, analysts expect Medifast to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Medifast Trading Down 1.2%

Medifast stock traded down $0.17 during trading hours on Thursday, hitting $13.85. 65,341 shares of the stock traded hands, compared to its average volume of 229,031. Medifast has a one year low of $11.57 and a one year high of $22.66. The firm's 50-day moving average price is $13.92 and its two-hundred day moving average price is $14.01. The company has a market cap of $152.21 million, a PE ratio of -21.31 and a beta of 0.86.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Medifast from a "hold" rating to a "buy" rating in a report on Thursday, May 1st.

Hedge Funds Weigh In On Medifast

Several large investors have recently made changes to their positions in MED. AQR Capital Management LLC increased its position in Medifast by 14.5% during the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer's stock valued at $2,693,000 after buying an additional 25,366 shares in the last quarter. Amundi raised its holdings in shares of Medifast by 43.5% during the first quarter. Amundi now owns 30,439 shares of the specialty retailer's stock valued at $398,000 after purchasing an additional 9,224 shares during the last quarter. Finally, Strs Ohio bought a new stake in Medifast in the 1st quarter worth approximately $78,000. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.